Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson's Disease

12 Sep 2024 12:00 CEST

Stockholm Sweden, September 12, 2024 - Navamedic ASA (OSE: NAVA), a Nordic
pharma company and reliable provider of high-quality products to hospitals and
pharmacies, has partnered with Alex Therapeutics, a digital health provider of
disease and drug companion apps, to aid in Parkinson's treatment management. The
app will be developed by Alex Therapeutics to support patients on Flexilev®, a
prescription treatment for Parkinson's disease.

The new companion app provides medication management support that addresses the
specific needs and challenges of people living with Parkinson's disease. The app
complements the next generation dose dispenser, OraFID®, containing Flexilev®,
offering a unique combination to support patients to adhere to precise and
individualized treatment regimens.

Parkinson's disease is a neurodegenerative disorder associated with loss of
motor skills and non-motor functions such as cognitive ability, which can make
it difficult to manage treatments. Digital health tools provide an opportunity
to support patients with functions such as reminders and treatment logs.

"We are excited to collaborate with Alex Therapeutics to enhance the lives of
Parkinson's patients through the companion app. This partnership not only
reflects our commitment to making the treatment more accessible and manageable,
but also underscores our dedication to easing the burden that patients face in
their day-to-day care," shares Kathrine Gamborg Andreassen, CEO of Navamedic.

CEO and Founder of Alex Therapeutics, John Drakenberg, states, "We are proud to
partner with Navamedic to bring this tailored solution to the Parkinson's
community. Our goal is to empower patients to manage their treatments
effectively, for better symptom relief and improved quality of life."

The companion app is set to be launched in Sweden, Norway and Denmark in the
coming year, with plans for further global expansion.

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). Senidose is a fully owned subsidiary of
Navamedic.
For more information, visit: www.navamedic.com

About Alex Therapeutics

Alex Therapeutics is a digital health company based in Stockholm and Boston that
partners with pharmaceutical companies to support people with treatment and
disease-related mental health challenges through clinically validated companion
apps. Alex Therapeutics specializes in oncology and rare diseases, which
typically entail complex treatment regimes and psychological distress. The
company has a strong regulatory team to support CE and FDA approval as well as
clinical evidence generation for SaMDs.
For more information, visit www.alextherapeutics.com

Media Contacts

Navamedic

Kathrine Gamborg Andreassen,
CEO
kathrine@navamedic.com

Alex Therapeutics

Meera Montan, Director of Growth

meera.montan@alextherapeutics.com

More information:
Access the news on Oslo Bors NewsWeb site